Document is current
Any future updates will be listed below
-
Authors
Stoklund Dittlau, Katarina https://orcid.org/0000-0003-2776-2892
Terrie, Lisanne https://orcid.org/0000-0002-6274-0624
Baatsen, Pieter https://orcid.org/0000-0003-4500-581X
Kerstens, Axelle
De Swert, Lim
Janky, Rekin’s https://orcid.org/0000-0001-5135-2469
Corthout, Nikky https://orcid.org/0000-0003-1176-7277
Masrori, Pegah https://orcid.org/0000-0001-8247-1866
Van Damme, Philip https://orcid.org/0000-0002-4010-2357
Hyttel, Poul
Meyer, Morten https://orcid.org/0000-0002-9571-1336
Thorrez, Lieven https://orcid.org/0000-0002-5896-6823
Freude, Kristine https://orcid.org/0000-0001-9480-2386
Van Den Bosch, Ludo
-
Funding
Funding for this research was provided by:
VIB
KU Leuven
Agentschap voor Innovatie door Wetenschap en Technologie
FWO-Vlaanderen
Target ALS
ALS Liga Belgie
The Belgian Government (Interuniversity Attraction Poles Program P7/16 initiated by the Belgian Federal Science Policy Office)
Fondation Thierry Latran
Association Belge contre les Maladies Neuro-Musculaires
- License Information
-
More Information
Article History
Received: 12 May 2022
Accepted: 16 December 2022
First Online: 18 January 2023
Declarations
:
: Written informed consent was obtained from all subjects who provided tissue samples. The use of patient fibroblasts for the generation of hiPSCs was approved by the ethics committee of University Hospital Leuven (n° S50354 and S63792), while the use of myoblasts was approved by the ethical commission (n° NH019-2020–04-02).
: Not applicable.
: The authors declare that they have no competing interests.
